# Salvage Ovarian FANG™ Vaccine + Carboplatinum

> **NCT01867086** · PHASE2 · COMPLETED · sponsor: **Gradalis, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Vigil™ Vaccine
- **DRUG:** Carboplatinum
- **DRUG:** Carboplatinum and Taxol

## Key facts

- **NCT ID:** NCT01867086
- **Lead sponsor:** Gradalis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-04-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01867086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01867086, "Salvage Ovarian FANG™ Vaccine + Carboplatinum". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01867086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*